Wijetunga NA, dos Anjos CH, Zhi WI, et al. - Using a single-institution database, researchers assessed the features of breast cancer patients with oligometastases (OM) managed with stereotactic ablative body radiotherapy (SABR) in order to detect factors related to local progression, distant metastasis progression, time to subsequent therapy, progression-free survival (PFS), as well as overall survival (OS). They found 79 patients who received SABR to OM. Using an institutional targeted sequencing platform, 27 patients underwent genetic testing of metastatic tumors. Progression occurred in 65% of patients, of these, 82% progressed outside of the radiation field, 18% encountered local failure, and 80% experienced oligoprogression. A median OS of 86 months and PFS of 33 months was obtained. Findings showed that SABR for oligometastatic breast cancer can confer long-term systemic disease control and survival. The ideal patient population for SABR to all sites of disease may include hormone receptor-positive patients with a long disease interval from initial diagnosis and limited systemic progression history.